🧬FDA Guidance on Heritable Genomic Alterations in Animals
Heritable Intentional Genomic Alterations in Animals: The Approval Process; Guidance for Industry; Availability
Summary
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry #187B entitled "Heritable Intentional Genomic Alterations in Animals: The Approval Process." This guidance clarifies FDA's requirements and recommendations for developers of intentional genomic alterations (IGAs) in animals. The guidance is one of two companion documents. "Heritable Intentional Genomic Alterations in Animals: The Approval Process" describes how the FDA approval process applies to heritable IGAs in animals. The companion final guidance, GFI #187A entitled "Heritable Intentional Genomic Alterations in Animals: Risk-Based Approach," describes FDA's risk-based regulatory approach to the oversight of heritable IGAs in animals.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$ - Med
The guidance outlines new regulatory requirements for developers of heritable intentional genomic alterations in animals, affecting biotechnology companies and related industries. The FDA's approval process and risk-based approach necessitate compliance among businesses engaged in genetic modifications, directly influencing operational and financial planning.